At this price the dividend yeld is 3.50%: it is a proxy of high grade bond and we think that the split between the core human pharma and the rest of the Group probably could come in late 2016.
Strong financial position.
Please remind yourself that this is just my personal view on the market. My analysis should NOT serve as any recommendation to buy or to sell.
If you find useful my analysis, please hit the LIKE button and follow me.